Status:
COMPLETED
SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia
Lead Sponsor:
University of Kansas Medical Center
Conditions:
BPH
Benign Prostatic Hyperplasia
Eligibility:
MALE
18+ years
Brief Summary
To compare intraoperative as well as postoperative outcomes of SOLTIVE Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP) vs Holmium Laser Enucleation of the Prostate. Our hypothesis is that u...
Detailed Description
Thulium laser is continuous wave laser which offers numerous potential benefits compared to alternative lasers and surgical procedures used for BPH. The SOLTIVE Laser system is a compact system which ...
Eligibility Criteria
Inclusion
- Patients must be 18 years of age or older
- Patients must be diagnosed with benign prostatic hyperplasia
- Patients must opt for surgical management of their BPH with laser enucleation
Exclusion
- Patients with a concomitant neurogenic bladder diagnosis (SCI, Parkinson, MS, cerebral palsy)
- Patients with prostate glands greater or equal to 200 grams
- Patients who are enrolled in other surgical or interventional trials at the time of this study are not eligible.
Key Trial Info
Start Date :
April 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 2 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04826887
Start Date
April 14 2021
End Date
May 2 2024
Last Update
October 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medcial Center
Kansas City, Kansas, United States, 66160